Table 3.
Results from phase II and III trials of antiangiogenic TKIs in combination with chemotherapy in NSCLC
| Reference | Phase | Regimen | Na | RR (%) | PFS (mo) | OS (mo) |
|---|---|---|---|---|---|---|
| Sorafenib | ||||||
| Flaherty 2008 (66) | I | CBDCA AUC 6 + PTX 225 mg/m2 + sorafenib 100, 200, or 400 mg twice daily. | 39 | 26 | 10.1 (melanoma) | NR |
| 3.4 (other tumor types) | ||||||
| Scagliotti 2010 (67) | III | CBDCA AUC 6 + PTX 225 mg/m2 + placebo. | 462 | 24 | 5.4 | 10.6 |
| CBDCA AUC 6 + PTX 225 mg/m2 + sorafenib 400 mg twice daily. | 464 | 27.4 | 4.6 | 10.7 | ||
| Cediranib | ||||||
| Gadgeel 2009 (68) | II | Pem 500 mg/m2 + cediranib 30 mg/day. | 31 | 16 | NR | NR |
| Vandetanib | ||||||
| De Boer 2009 (69) | I | Pem 500 mg/m2 + vandetanib 100 mg/day. | 10 | 10 | NR | NR |
| Pem 500 mg/m2 + vandetanib 300 mg/day. | 11 | 0 | NR | NR | ||
| Heymach 2008 (70) | II | CBDCA AUC 6 + PTX 200 mg/m2 + placebo. | 52 | 25 | ∼6 (23 weeks) | 12.6 |
| CBDCA AUC 6 + PTX 200 mg/m2 + vandetanib 300 mg/day. | 56 | 32 | ∼6 (24 weeks) | 10.2 | ||
| Heymach 2007 (71) | II | TXT 75 mg/m2 + placebo. | 41 | 12 | 2.8 | 13.4 |
| TXT 75 mg/m2 + vandetanib 100 mg/day. | 42 | 26 | 4.3 | 13.1 | ||
| TXT 75 mg/m2 + vandetanib 300 mg/day. | 44 | 18 | 4.0 | 7.9 | ||
| Herbst 2010 (72) | III | TXT 75 mg/m2 + placebo. | 697 | 10 | 3.2 | 9.9 |
| TXT 75 mg/m2 + vandetanib 100 mg/day. | 694 | 17 | 4.0 | 10.3 | ||
| De Boer 2009 (73) | III | Pem 500 mg/m2 + placebo. | 278 | 7.9 | NR | NR |
| Pem 500 mg/m2 + vandetanib 100 mg/day. | 256 | 19.1 | NR | NR | ||
a
Patients evaluable for efficacy.
Abbreviations. AUC: area under the curve; CBDCA: carboplatin; NR: not reported; NSCLC: non-small cell lung cancer; OS: overall survival; Pem: pemetrexed; PFS: progressionfree survival; PTX: paclitaxel; RR: response rate; TKI: tyrosine kinase inhibitor; TXT: docetaxel.